Showing 1 to 8 of 8 results
EMA Reverses Alzheimer's Drug Block, Approves Donanemab Under Strict Protocols
The European Medicines Agency (EMA) reversed its decision to block Donanemab, a new Alzheimer's treatment, approving it for early-stage patients with at most one copy of a specific gene under strict safety protocols after initially deeming the risks outweighed the benefits; Donanemab slows Alzheimer...
EMA Reverses Alzheimer's Drug Block, Approves Donanemab Under Strict Protocols
The European Medicines Agency (EMA) reversed its decision to block Donanemab, a new Alzheimer's treatment, approving it for early-stage patients with at most one copy of a specific gene under strict safety protocols after initially deeming the risks outweighed the benefits; Donanemab slows Alzheimer...
Progress
40% Bias Score
EMA Conditionally Approves Alzheimer's Drug Donanemab Under Strict Safety Protocols
The European Medicines Agency (EMA) conditionally approved the Alzheimer's drug donanemab (Kisunla) for patients with one or zero copies of a gene linked to increased risk, after initially rejecting it due to the risk of brain swelling and bleeding; the drug will be available only under strict safet...
EMA Conditionally Approves Alzheimer's Drug Donanemab Under Strict Safety Protocols
The European Medicines Agency (EMA) conditionally approved the Alzheimer's drug donanemab (Kisunla) for patients with one or zero copies of a gene linked to increased risk, after initially rejecting it due to the risk of brain swelling and bleeding; the drug will be available only under strict safet...
Progress
32% Bias Score
EMA Blocks Alzheimer's Drug Donanemab Due to Fatal Side Effects
The European Medicines Agency (EMA) blocked Lilly's Alzheimer's drug, donanemab (Kisunla), due to potentially fatal side effects, despite its approval in the US and UK; the drug slowed Alzheimer's progression by 35% in trials but caused three deaths, two linked to a gene increasing Alzheimer's risk;...
EMA Blocks Alzheimer's Drug Donanemab Due to Fatal Side Effects
The European Medicines Agency (EMA) blocked Lilly's Alzheimer's drug, donanemab (Kisunla), due to potentially fatal side effects, despite its approval in the US and UK; the drug slowed Alzheimer's progression by 35% in trials but caused three deaths, two linked to a gene increasing Alzheimer's risk;...
Progress
52% Bias Score
NHS to Re-evaluate Alzheimer's Drugs Amidst Cost and Efficacy Concerns
The NHS is reviewing its decision to block two Alzheimer's drugs, lecanemab and donanemab, which slow disease progression by up to 35 percent but cost approximately £1 billion annually, after public and advocacy group pressure.
NHS to Re-evaluate Alzheimer's Drugs Amidst Cost and Efficacy Concerns
The NHS is reviewing its decision to block two Alzheimer's drugs, lecanemab and donanemab, which slow disease progression by up to 35 percent but cost approximately £1 billion annually, after public and advocacy group pressure.
Progress
56% Bias Score
EMA Conditionally Approves Alzheimer's Drug Donanemab Under Strict Monitoring
The European Medicines Agency conditionally approved Eli Lilly's Donanemab for early-stage Alzheimer's patients with one or zero copies of a specific gene, reversing its initial rejection due to the risk of fatal brain swelling and bleeding, mirroring a similar approval process for Lecanemab.
EMA Conditionally Approves Alzheimer's Drug Donanemab Under Strict Monitoring
The European Medicines Agency conditionally approved Eli Lilly's Donanemab for early-stage Alzheimer's patients with one or zero copies of a specific gene, reversing its initial rejection due to the risk of fatal brain swelling and bleeding, mirroring a similar approval process for Lecanemab.
Progress
40% Bias Score
Donanemab Approved for Early-Stage Alzheimer's with Stricter Guidelines
Donanemab, a new Alzheimer's drug, received conditional approval in Europe, slowing disease progression by up to six months in early stages for patients with mild cognitive impairment and only one copy of the ApoE4 gene, but with risks of brain swelling and bleeding.
Donanemab Approved for Early-Stage Alzheimer's with Stricter Guidelines
Donanemab, a new Alzheimer's drug, received conditional approval in Europe, slowing disease progression by up to six months in early stages for patients with mild cognitive impairment and only one copy of the ApoE4 gene, but with risks of brain swelling and bleeding.
Progress
48% Bias Score
EMA Rejects Alzheimer's Drug Donanemab Due to Safety Concerns
The European Medicines Agency (EMA) rejected Eli Lilly's Alzheimer's drug, donanemab, due to concerns about deadly side effects, impacting 7 million Europeans with Alzheimer's despite its 35% efficacy in slowing dementia progression in trials; the decision contrasts with the eventual approval of a s...
EMA Rejects Alzheimer's Drug Donanemab Due to Safety Concerns
The European Medicines Agency (EMA) rejected Eli Lilly's Alzheimer's drug, donanemab, due to concerns about deadly side effects, impacting 7 million Europeans with Alzheimer's despite its 35% efficacy in slowing dementia progression in trials; the decision contrasts with the eventual approval of a s...
Progress
40% Bias Score
£60,000 Alzheimer's Drug Faces Criticism Over Limited Benefits and High Risks
A new £60,000-a-year Alzheimer's drug, Donanemab, offered privately in London, is criticized for minimal benefits and risks like brain swelling and bleeding, despite UK regulator approval; NHS rejected it due to cost-ineffectiveness.
£60,000 Alzheimer's Drug Faces Criticism Over Limited Benefits and High Risks
A new £60,000-a-year Alzheimer's drug, Donanemab, offered privately in London, is criticized for minimal benefits and risks like brain swelling and bleeding, despite UK regulator approval; NHS rejected it due to cost-ineffectiveness.
Progress
60% Bias Score
Showing 1 to 8 of 8 results